Campbell Schmidt1, Jarad M Martin2, Eric Khoo3, Ashley Plank4, Roger Grigg5. 1. School of Medicine, University of Queensland, Queensland, Australia. 2. Department of Radiation Oncology, Calvary Mater Newcastle, Newcastle, Australia. 3. Radiation Oncology Queensland, St Andrew's Cancer Care Center, St Andrew's Hospital, Toowoomba, Queensland, Australia. 4. Oncology Research Australia, Australia. 5. Department of Otolaryngology Head and Neck Surgery, Toowoomba Rural Clinical School, University of Queensland, Queensland, Australia.
Abstract
BACKGROUND: Given its metastatic potential and high incidence, cutaneous squamous cell carcinoma of the head and neck (SCCHN) has significant morbidity and mortality. METHODS: We conducted a retrospective review of prospectively collected data for 113 consecutive patients with nodal metastatic cutaneous SCCHN treated surgically with curative intent in a regional center. Survival curves were generated by the Kaplan-Meier method. RESULTS: Five-year overall survival (OS), disease-specific survival (DSS), and disease-free survival (DFS) were 80%, 83%, and 75%, respectively. Twenty-six patients (23%) relapsed, with 92% of relapses occurring within 2 years of surgery. Immunosuppression (p = .008) and N classification (p = .043) predicted decreased DFS on univariate analysis. On multivariate analysis, only immunosuppression independently predicted DFS (p = .034). CONCLUSION: This study validates the current N classification system, supports the adverse effect of immunosuppression, and suggests that intense follow-up for 2 years postsurgery is warranted. Survival at this regional center is comparable to that achieved at metropolitan tertiary cancer centers.
BACKGROUND: Given its metastatic potential and high incidence, cutaneous squamous cell carcinoma of the head and neck (SCCHN) has significant morbidity and mortality. METHODS: We conducted a retrospective review of prospectively collected data for 113 consecutive patients with nodal metastatic cutaneous SCCHN treated surgically with curative intent in a regional center. Survival curves were generated by the Kaplan-Meier method. RESULTS: Five-year overall survival (OS), disease-specific survival (DSS), and disease-free survival (DFS) were 80%, 83%, and 75%, respectively. Twenty-six patients (23%) relapsed, with 92% of relapses occurring within 2 years of surgery. Immunosuppression (p = .008) and N classification (p = .043) predicted decreased DFS on univariate analysis. On multivariate analysis, only immunosuppression independently predicted DFS (p = .034). CONCLUSION: This study validates the current N classification system, supports the adverse effect of immunosuppression, and suggests that intense follow-up for 2 years postsurgery is warranted. Survival at this regional center is comparable to that achieved at metropolitan tertiary cancer centers.
Authors: Agnieszka K Thompson; Benjamin F Kelley; Larry J Prokop; M Hassan Murad; Christian L Baum Journal: JAMA Dermatol Date: 2016-04 Impact factor: 10.282
Authors: Joshua Lubov; Mathilde Labbé; Krystelle Sioufi; Grégoire B Morand; Michael P Hier; Manish Khanna; Khalil Sultanem; Alex M Mlynarek Journal: J Otolaryngol Head Neck Surg Date: 2021-09-07
Authors: Guilherme Rabinowits; Michael R Migden; Todd E Schlesinger; Robert L Ferris; Morganna Freeman; Valerie Guild; Shlomo Koyfman; Anna C Pavlick; Neil Swanson; Gregory T Wolf; Scott M Dinehart Journal: JID Innov Date: 2021-08-25